Atara Biotherapeutics, Inc. Profile Avatar - Palmy Investing

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical…

Biotechnology
US, South San Francisco [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Atara Biotherapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ATRA's Analysis
CIK: 1604464 CUSIP: 046513107 ISIN: US0465131078 LEI: - UEI: -
Secondary Listings
ATRA has no secondary listings inside our databases.